Stichworte
Koronarkrankheit ×
Zeige mehr Stichworte
Inhaltsverzeichnis
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

132 Suchergebnisse.

Persönliches Interview SHIP-Trend-1 Herz-Kreislauf-Erkrankungen

- 02.11.17 - 1 Formular, 1 Itemgruppe, 5 Datenelemente, 1 Sprache
Itemgruppe: Herz-Kreislauf-Erkrankungen
Herz-Kreislauf-Erkrankungen form of SHIP Study (Study of Health in Pomerania), conducted by the University of Greifswald. SHIP unique domain name TREND.TREND1.INT.KHK.KHK. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html.
 Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617

Eligibility Multiple Conditions NCT01597882

- 17.01.19 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Improving Monitoring of Patients Receiving Case Management; ODM derived from: https://clinicaltrials.gov/show/NCT01597882

Eligibility Coronary Heart Disease NCT02045134

- 15.01.19 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery; ODM derived from: https://clinicaltrials.gov/show/NCT02045134

Eligibility Coronary Heart Disease NCT01255540

- 15.01.19 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
After Eighty Study; ODM derived from: https://clinicaltrials.gov/show/NCT01255540

Pharmacokinetics of an oral contraceptive co-administered with Albiglutide in women - 107032 - Adjudication Events - Heart Failure

- 04.01.19 - 1 Formular, 15 Itemgruppen, 86 Datenelemente, 1 Sprache
Itemgruppen: Administrative data, Hospitalization for Heart Failure, Clinical Symptoms of Heart Failure, Investigative Evidence of Structural or Functional Heart Disease, Chest X-Ray, Echocardiography, Left ventricular systolic dysfunction / impairment, Significant valvular heart disease, BNP (B-type natriuretic peptide) or NT-proBNP (N-terminal proBNP), Peak BNP/NT-proBNP value + the laboratory upper reference limit, BNP, NT-proBNP, Other Investigations, Treatment, Description of Event
Study ID: 107032 Clinical Study ID: GLP107032 Study Title: An open-label study to evaluate the pharmacokinetics of an oral contraceptive containing Norethindrone and Ethinyl Estradiol when co-administered with GSK716155 in healthy adult female subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01077505 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: albiglutide Trade Name: Tanzeum,Eperzan Study Indication: Diabetes Mellitus, Type 2

Eligibility Coronary Heart Disease NCT01942044

- 16.12.18 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Relation Among Shear Stress Distribution, Stent Design, and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES); ODM derived from: https://clinicaltrials.gov/show/NCT01942044

Eligibility Coronary Disease NCT01667757

- 16.12.18 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Optimal Physiologic Intravascular Ultrasound Imaging Criteria After Drug Eluting Stent Implantation; ODM derived from: https://clinicaltrials.gov/show/NCT01667757

Liver biopsy GSK study Chronic Coronary Heart Disease NCT00799903

- 06.12.18 - 1 Formular, 14 Itemgruppen, 157 Datenelemente, 1 Sprache
Itemgruppen: Date of liver biopsy, Liver Biopsy size, Liver Biopsy Final Diagnosis, Liver Architecture, Description of Liver Cells or Hepatocytes, Liver Cell or Hepatocyte Inclusions or Vacuoles, Hepatocyte or Liver Cell Nuclear Abnormalities, Liver or Lobular Infiltrates, Portal Tract Inflammation, Bile Ducts, Portal Veins, Liver Infections, Liver: Parasites or Ova, Histologic Staining or Additional Studies Obtained
Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Liver biopsy - Repeating form (Unscheduled/Dynamic visit)

Eligibility Coronary Heart Disease NCT01654653

- 04.02.18 - 1 Formular, 2 Itemgruppen, 11 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Efficacy and Safety of Hypertonic Sodium Lactate Solution Compared With 6% HES Solution in CABG Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01654653

Eligibility Coronary Heart Disease NCT01021930

- 04.02.18 - 1 Formular, 2 Itemgruppen, 21 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT; ODM derived from: https://clinicaltrials.gov/show/NCT01021930

Eligibility Coronary Heart Disease NCT00959972

- 04.02.18 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00959972

Eligibility Coronary Heart Disease NCT00950339

- 04.02.18 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine; ODM derived from: https://clinicaltrials.gov/show/NCT00950339